Angels for Change submitted formal comments to the U.S. Department of Commerce Section 232 investigation into pharmaceutical imports and national security. Our statement respectfully urges the Administration to exempt essential pharmaceutical products—especially Generic Sterile Injectables (GSIs)—from potential tariffs, which could worsen the already fragile drug supply chain and lead to increased shortages.
We highlighted the economic and systemic drivers behind drug shortages and shared our concerned that, given these broken economics, pharmaceutical tariffs would inadvertently cause disruptions that could have devastating impacts on routine and critical health care in the United States for patients.
Our recommendations include payment reform to reward manufacturing reliability and resiliency, partnering with multi-stakeholder groups to build the resiliency, and investment in mitigation tools like our Drug Shortage Hotline, Project PROTECT and Project GOLD.
View the full submission.